Immune and strain surveillance of the Streptococcus pneumoniae: Tools to study the impact of pneumococcal conjugate vaccination
PhD ceremony: Ms. K.E.M. Elberse, 12.45 uur, Aula Academiegebouw, Broerstraat 5, Groningen
Dissertation: Immune and strain surveillance of the Streptococcus pneumoniae: Tools to study the impact of pneumococcal conjugate vaccination
Promotor(s): prof. H. Grundmann
Faculty: Medical Sciences
In 2006, the pneumococcal vaccine was introduced in the national immunization program in the Netherlands. The vaccine is administered to children in the first year of their life in a 2-3-4-months vaccination scheme, and an extra vaccination at 11 months. It protects against severe infections such as meningitis and pneumonia. The vaccine is directed against the 7 most important serotypes (out of 90) of the pneumococcus. In 2011, the vaccine was replaced by a vaccine that is directed against 10 different serotypes.
When someone is infected by a pneumococcus, or a person is carrier without symptoms, antibodies are produced in the human body. Using a new test, we determined the concentrations of antibodies against 13 of the most important serotypes in the Dutch population. The results inform us about the natural acquired antibody concentrations against the pneumococcus in the Dutch population before the introduction of the vaccine in the national program. The data showed no relationship between natural acquired antibody concentrations and the number of severe pneumococcal disease.
Since the introduction of the vaccine, a decline of the number of severe pneumococcal disease in children was seen. The selective pressure of the vaccine induced changes in the occurrence of serotypes, but does not yet seem to influence the genetic background of the pneumococcal population. Variants within serotypes seem to occur and these strains may avoid the vaccine immunity, but additional research should be done to elucidate this.
Last modified: | 13 March 2020 01.02 a.m. |
More news
-
29 November 2023
UMCG opent nieuwe faciliteit voor microbioomonderzoek 
Vandaag opent het UMCG de Groningen Microbioom Hub: een nieuwe faciliteit met state-of-the-art technologie waarin alle UMCG-expertise op het gebied van microbioomonderzoek samenkomt. Dit zorgt voor unieke mogelijkheden in onderzoek en maakt nieuwe...
-
28 November 2023
Science: more exciting than showbiz
Science often seems very complicated. Most people probably don't really know what researchers do, and what it takes to make a breakthrough. That is why it is important to keep the general public informed of what is happening in science, says Iris...
-
13 November 2023
UMCG beantwoordt vragen patiënten met hulp van AI
Het UMCG zet kunstmatige intelligentie (artificial intelligence, afgekort AI) in om zorgverleners te helpen bij het beantwoorden van schriftelijke vragen van patiënten. Dit gebeurt in samenwerking met andere ziekenhuizen vanuit de EPIC Nederlandse...